Off-label use of orphan medicinal products: a Belgian qualitative study

被引:15
|
作者
Dooms, Marc [1 ]
Cassiman, David [2 ]
Simoens, Steven [3 ]
机构
[1] Univ Hosp Leuven, Ctr Clin Pharmacol, Herestr 49, B-3000 Leuven, Belgium
[2] Univ Hosp Leuven, Div Gastroenterol Hepatol, Herestr 49, B-3000 Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Herestr 49,POB 521, B-3000 Leuven, Belgium
关键词
Off-label use; Unlicensed use; Orphan medicinal products; Rare diseases; Safety; Efficacy; PERSPECTIVE;
D O I
10.1186/s13023-016-0507-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective of this study was to map off-label use of orphan medicinal products in Belgium in terms of attitude towards off-label prescribing, factors influencing off-label prescribing, disclosure of information towards the patient, reporting of off-label use, risks and consequences. Most of the EMA authorized orphan drugs are fully reimbursed in Belgium under well-defined circumstances. Moreover, a "Special Solidarity Fund" takes care of some specific cases eventually prescribed off-label. Methods: Semi-structured interviews with seven physicians with expertise in the treatment with and six experts in the reimbursement of orphan medicinal products in Belgium. This task was performed by five last-year pharmacy students after having studied profoundly the medical literature around off-label prescribing. They had no previous contact with the participants. Results: Most participants do agree with the off-label use if the medicinal product is quite safe and well-tolerated, if the on-label indication is rather general and when all other options have failed in some specific, evidence-based indications, especially in children. Before starting off-label use, the patient/family needs to be fully and clearly informed. The treatment is not reimbursed but sometimes sponsored by the company or by charity funds. Reporting of the outcome is necessary to avoid losing valuable information. The prescriber is responsible and can be held accountable. Conclusions: While there is support from physicians and reimbursement experts, there is also concern in case of off-label use, mainly for reasons of patient safety especially when medicinal products are prescribed off-label in the absence of medical or scientific justification and driven by cost-containment motives.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [1] Off-label use of orphan medicinal products: a Belgian qualitative study
    Marc Dooms
    David Cassiman
    Steven Simoens
    Orphanet Journal of Rare Diseases, 11
  • [2] OFF-LABEL USE OF MEDICINAL PRODUCTS - LEGAL RULES AND PRACTICES
    Jaroszynski, Janusz
    Mela, Aneta
    Furtak-Niczyporuk, Marzena
    Poniatowski, Lukasz A.
    Dabrowski, Jan
    Czajka-Belz, Anna
    Zimmermann, Agnieszka
    Dreher, Piotr
    Drop, Bartlomiej
    Staniszewska, Anna
    ACTA POLONIAE PHARMACEUTICA, 2019, 76 (04): : 621 - 628
  • [3] Unlicensed and off-label use of medicinal products.: An overview
    García-Sáiz, M. M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 : 13 - 14
  • [4] Off-label and unlicensed use of medicinal products in the neonatal setting in the Slovak Republic
    Schweigertova, Jana
    Durisova, Alena
    Dolnikova, Dana
    Ondriasova, Elena
    Balazova, Martina
    Slezakova, Veronika
    Kuzelova, Magdalena
    PEDIATRICS INTERNATIONAL, 2016, 58 (02) : 126 - 131
  • [5] Off-Label Use of Medicines: A Comparative Study on the Regulation of Medicinal Products in Selected European Union Member States
    Soares Junior, Wolney da Cunha
    EUROPEAN JOURNAL OF RISK REGULATION, 2022, 13 (02) : 311 - 332
  • [6] Off-label use of antipsychotics: Rethinking "off-label"
    Groleger, Urban
    PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
  • [7] The use of intravenous immunoglobulins in registered and off-label conditions in Belgian hospitals
    Simoens, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2012, 34 (01) : 252 - 252
  • [8] Recommendations for the so-called off-label use of medicinal products in COVID-19 patients
    Sustek, P.
    Holcapek, T.
    Solc, M.
    ANESTEZIOLOGIE A INTENZIVNI MEDICINA, 2020, 31 (03): : 119 - 123
  • [9] Off-label use in cardiac surgery ["Off-label use" in der Herzchirurgie]
    Fenger H.
    Löher A.
    Sindermann J.R.
    Scheld H.H.
    Schmidt C.
    Hoffmeier A.
    Zeitschrift für Herz-,Thorax- und Gefäßchirurgie, 2009, 23 (6) : 345 - 348
  • [10] Off-label use and G-BA. Legal framework for off-label use
    Brucklacher, U.
    Brockmeyer, N. H.
    Riedel, C.
    HAUTARZT, 2013, 64 (10): : 736 - 742